Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 1/20 | 0.50 |
| ▸ | P2RX7 | Q99572 | 4/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.34 |
| ▸ | GRM5 | P41594 | 1/20 | 0.34 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.33 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.33 |
| ▸ | DAO | P14920 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | HTR1A | P08908 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25387056 | 0.84 | DRD2 (0.44) | TRPA1P2RX7TSHRL3MBTL1SLC6A4 | |
| SCHEMBL31283719 | 0.84 | DRD2 (0.44) | TRPA1P2RX7TSHRL3MBTL1SLC6A4 | |
| SCHEMBL10361527 | 0.81 | USP2 (0.42) | TRPA1USP2TSHRSLC6A4SLC6A3 | |
| SCHEMBL26081139 | 0.80 | USP2 (0.41) | P2RX7USP2TSHRHTR1A | |
| SCHEMBL26081069 | 0.80 | TRPA1 (0.47) | TRPA1P2RX7L3MBTL1SLC6A4SLC6A3 | |
| SCHEMBL26081174 | 0.78 | USP2 (0.39) | TRPA1P2RX7USP2TSHR | |
| SCHEMBL26081213 | 0.77 | USP2 (0.41) | TRPA1P2RX7USP2TSHRSLC6A4 | |
| SCHEMBL26081078 | 0.76 | P2RX7 (0.44) | TRPA1P2RX7USP2TSHRL3MBTL1 | |
| SCHEMBL26081042 | 0.76 | KDM4E (0.41) | TRPA1USP2TSHRL3MBTL1TDP1 | |
| SCHEMBL26081247 | 0.75 | USP2 (0.44) | TRPA1P2RX7USP2TSHRL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230312522-A1 | CYP46A1 INHIBITORS AND METHODS OF USE THEREOF | SAGE THERAPEUTICS, INC. | 2023-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230312522-A1 | CYP46A1 INHIBITORS AND METHODS OF USE THEREOF | CYP46A1, CYP26A1, CYP4A22 | TRPA1 3975/4885P2RX7 2962/4885USP2 1918/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.